Expand APLS Menu
APLS MENU

APLS Latest Press Releases

-- December 3, 2025 --

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI (pegcetacoplan) for C3G and Primary IC-MPGN Globe Newswire 5:05 PM

-- November 25, 2025 --

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- November 12, 2025 --

Apellis Announces 5-Year GALE Data Showing SYFOVRE (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years Globe Newswire 7:00 AM

-- November 5, 2025 --

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference Globe Newswire 7:00 AM

-- October 30, 2025 --

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results Globe Newswire 7:05 AM

-- October 20, 2025 --

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week Globe Newswire 7:00 AM

-- October 16, 2025 --

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results Globe Newswire 7:00 AM

-- August 27, 2025 --

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- July 31, 2025 --

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results Globe Newswire 7:05 AM

-- July 28, 2025 --

FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older Globe Newswire 7:19 PM

-- July 24, 2025 --

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results Globe Newswire 7:00 AM

-- July 15, 2025 --

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes